<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292796</url>
  </required_header>
  <id_info>
    <org_study_id>2014OPH03L(104-0614)</org_study_id>
    <secondary_id>REC 15/EE/0239</secondary_id>
    <nct_id>NCT03292796</nct_id>
  </id_info>
  <brief_title>RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.</brief_title>
  <acronym>CMO</acronym>
  <official_title>A Randomised Control Study to Investigate if the Continuation of Prostaglandin Analogue Treatments in the Post-operative Phase of Glaucoma Patients Undergoing Cataract Surgery Increases the Incidence of Cystoid Macular Oedema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Julie Dawson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norfolk and Norwich University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-operative cystoid macular oedema (CMO) is a common complication causing visual loss&#xD;
      following routine cataract surgery. This complication is more prevalent in eyes with&#xD;
      excessive inflammation as they heal from surgery.&#xD;
&#xD;
      Prostaglandin analogues (PGA) are the commonest first line drugs used in the long-term&#xD;
      treatment of primary open angle glaucoma (POAG)- where they reduce the pathologically high&#xD;
      pressure in the eye. Prostaglandins are inflammatory mediators.&#xD;
&#xD;
      In the post-operative care of glaucoma patients undergoing cataract surgery, there is a&#xD;
      clinical dilemma whether to stop or continue the use of prostaglandin eye drops. Clinical&#xD;
      practice is completely dichotomized between continuing and stopping PGA treatment in the&#xD;
      postoperative period. There is conflicting scientific literature on the effect of PGA on the&#xD;
      incidence of CMO; and only a single randomized control trial (Miyake K, Arch Ophthalmol 1999,&#xD;
      117:34-40), where the post operative regime is not applicable to present practice, compared&#xD;
      the incidence of CMO following routine cataract surgery in POAG on PGA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to answer the common clinical question of whether or not to stop PGA after&#xD;
      routine cataract surgery. Cataract surgery is the commonest operation performed on the NHS&#xD;
      and the prevalence of glaucoma is 5% in the population over 80 years old. Thus the clinical&#xD;
      dilemma is a common one.&#xD;
&#xD;
      A current literature search reveals that a divided opinion over whether PGAs do increase the&#xD;
      incidence of CMO. No study has yet established a causal relationship between the use of PGAs&#xD;
      and the development of CMO. Anecdotal reports and small case series have associated&#xD;
      peri-operative PGA use with the occurrence of CMO (Henderson BA et al, 2007 J Cataract&#xD;
      Refract Surg 33:1550-1558; Moroi SE et al, 1999, Ophthalmology 106:1024-1029). Whilst, in&#xD;
      direct contrast, other authors argue CMO as a rare phenomenon and the causative relationship&#xD;
      is debated (Schumer RA et al 2000, Curr Opin Ophthalmol 11:94-100; Miyake K et al 2003 J&#xD;
      Cataract Refract Surg 29:1800-1810)&#xD;
&#xD;
      The most similar previous study to the one proposed, was by Miyake K et al. (Arch Ophthalmol&#xD;
      1999, 117:34-40). The key difference, though, is in the postoperative drop regime of&#xD;
      fluorometholone and diclofenac in that paper and current UK clinical practice of using&#xD;
      dexamethasone. In terms of study design, this paper used an invasive method of investigating&#xD;
      CMO by fundus fluorescein angiography compared to OCT proposed here.&#xD;
&#xD;
      A recent case report by Agange N &amp; Mosaed S (Journal of Ophthalmology, 2010) concludes with&#xD;
      'conclusions about causal relationships cannot be made without well-designed, prospective&#xD;
      clinical trials addressing this issue'.&#xD;
&#xD;
      This study will therefore use drops that are routinely used in current UK clinical practice&#xD;
      and add to the body of evidence that helps answer the question should PGAs be continued after&#xD;
      cataract surgery so as to prevent the progression of glaucoma in patients.&#xD;
&#xD;
        -  Aim&#xD;
&#xD;
             -  This study investigates if the occurrence of CMO after cataract surgery is affected&#xD;
                by the use of PGA drops by patients with glaucoma&#xD;
&#xD;
             -  The null hypothesis states there is no increase in the incidence of CMO on OCT&#xD;
                scanning in the 4 weeks following cataract surgery whether PGA eye drops continue&#xD;
                or are stopped.&#xD;
&#xD;
        -  Design&#xD;
&#xD;
             -  Randomised control study with parallel group design&#xD;
&#xD;
             -  Single masking of outcome assessors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Actual">July 25, 2020</completion_date>
  <primary_completion_date type="Actual">October 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The patient is not masked as to treatment group and are aware of whether they are to continue or stop the PGA drops&#xD;
The care providers are not masked as to treatment group&#xD;
Outcome assessors are masked as to the patient's treatment group for their analysis of the OCT scans over the 4 week peri-operative period.&#xD;
The scans are recorded with only the randomised identifier.&#xD;
This is to reduce bias in the analysis of the scans&#xD;
Unmasking of each patient will occur after their analysis of their week 4 OCT scan</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of cystoid macula oedema (CMO) at 4 weeks post operatively</measure>
    <time_frame>4 weeks post operatively</time_frame>
    <description>Occurrence of cystoid macula oedema (CMO) at 4 weeks post operatively.Cystoid macular oedema will be defined as an increase in the central macula thickness on the OCT with characteristic intraretinal changes in the 4 weeks following surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP) at 4 weeks post-operatively.</measure>
    <time_frame>4 weeks post operatively</time_frame>
    <description>Intraocular pressure (IOP) at 4 weeks post-operatively. Intraocular pressure will be measured by Goldmann applanation tonometry, the standard method used in clinical practice to monitor glaucoma. This forms part of the standard post-operative examination following surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Open Angle Glaucoma and Cataract</condition>
  <arm_group>
    <arm_group_label>Stop prostaglandin eye drops post op</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue prostaglandin eye drops post op</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostaglandins</intervention_name>
    <arm_group_label>Continue prostaglandin eye drops post op</arm_group_label>
    <arm_group_label>Stop prostaglandin eye drops post op</arm_group_label>
    <other_name>Latanoprost Travaprost Bimatoprost Tafluprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary open-angle glaucoma and ocular hypertensive subjects undergoing cataract&#xD;
             surgery (routine phacoemulsification and intraocular lens implantation) AND on current&#xD;
             topical glaucoma treatment with a prostaglandin analogue eye drop for at least 2&#xD;
             months prior to cataract surgery.&#xD;
&#xD;
          -  Subjects capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with additional risk factors for macula oedema (eg. diabetic retinopathy,&#xD;
             previous macula oedema, uveitis)&#xD;
&#xD;
          -  Subjects with advanced glaucoma&#xD;
&#xD;
               -  Advanced visual field loss (Humphrey Mean Deviation &gt;-12dB)&#xD;
&#xD;
               -  Advanced glaucomatous disc changes (vertical cup-to-disc ratio &gt;0.9)&#xD;
&#xD;
          -  Subjects with non-controlled intraocular pressure (IOP) (pre-operative IOP &gt;22 mmHg)&#xD;
&#xD;
          -  Any contra-indication to the use of topical prostaglandin drops&#xD;
&#xD;
          -  Any contra-indication to the use of routine post-operative dexamethasone 0.1% eye&#xD;
             drops&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients unable to give informed consent&#xD;
&#xD;
          -  Intra-operative complication during cataract phacoemulsification and intraocular lens&#xD;
             implantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuwan Niyadurupola, Consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Ophthalmologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Agange N, Mosaed S. Prostaglandin-induced cystoid macular edema following routine cataract extraction. J Ophthalmol. 2010;2010:690707. doi: 10.1155/2010/690707. Epub 2010 Nov 7.</citation>
    <PMID>21076526</PMID>
  </reference>
  <reference>
    <citation>Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007 Sep;33(9):1550-8.</citation>
    <PMID>17720069</PMID>
  </reference>
  <reference>
    <citation>Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999 Jan;117(1):34-40.</citation>
    <PMID>9930158</PMID>
  </reference>
  <reference>
    <citation>Miyake K, Ibaraki N, Goto Y, Oogiya S, Ishigaki J, Ota I, Miyake S. ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003 Sep;29(9):1800-10.</citation>
    <PMID>14522305</PMID>
  </reference>
  <reference>
    <citation>Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, Abrams GW, Johnson MW. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999 May;106(5):1024-9.</citation>
    <PMID>10328408</PMID>
  </reference>
  <reference>
    <citation>Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000 Apr;11(2):94-100. Review.</citation>
    <PMID>10848227</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Norfolk and Norwich University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Julie Dawson</investigator_full_name>
    <investigator_title>Research Services Manager</investigator_title>
  </responsible_party>
  <keyword>Open Angle Glaucoma</keyword>
  <keyword>Cataract</keyword>
  <keyword>Phacoemulsification,</keyword>
  <keyword>Cystoid Macular Oedema,</keyword>
  <keyword>Prostaglandin Analogues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

